Status:
UNKNOWN
VITamin D and OmegA-3 TriaL: Effects on Mammographic Density and Breast Tissue
Lead Sponsor:
Brigham and Women's Hospital
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Benign Breast Disease
Eligibility:
FEMALE
55-67 years
Phase:
NA
Brief Summary
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial in 25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU...
Detailed Description
Mammographic density is one of the strongest risk factors for breast cancer. It is predictive of breast cancer risk for at least 10 years in the futue and has been suggested as a surrogate marker of b...
Eligibility Criteria
Inclusion
- part of parent VITAL trial
Exclusion
- Men,
- women with breast cancer
Key Trial Info
Start Date :
July 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2023
Estimated Enrollment :
3894 Patients enrolled
Trial Details
Trial ID
NCT02239874
Start Date
July 1 2012
End Date
October 1 2023
Last Update
April 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115